We updated the design of this site on September 25th. Learn more.

Oral Miglustat in Adult Patients With Stable Type 1 Gaucher Disease

This study has been completed.

Sponsor:

ClinicalTrials.gov Identifier:

NCT00319046

First Posted: April 27, 2006

Last Update Posted: June 1, 2012

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.

Information provided by (Responsible Party):

Actelion

Purpose

Although miglustat has been approved as a treatment for mild to moderate type 1 Gaucher disease in patients who are unsuitable for enzyme replacement therapy (ERT), more data are required to establish the long term efficacy, safety and tolerability of miglustat in maintaining diseases stability after a switch from ERT.

Condition	Intervention	Phase
Type 1 Gaucher Disease	Drug: miglustat	Phase 3


Study Type:	Interventional
Study Design:	Intervention Model: Single Group Assignment Masking: None (Open Label) Primary Purpose: Treatment
Official Title:	Open-label, Non Comparative, Multi-center Study to Evaluate the Long Term Efficacy, Safety and Tolerability of Oral Miglustat as a Maintenance Therapy After a Switch From Enzyme Replacement Therapy in Adult Patients With Stable Type 1 Gaucher Disease

Resource links provided by NLM:

Genetics Home Reference related topics: Gaucher disease

MedlinePlus related topics: Gaucher Disease

Drug Information available for: Miglustat

Genetic and Rare Diseases Information Center resources: Gaucher Disease Gaucher Disease Type 1 Sphingolipidosis

U.S. FDA Resources

Further study details as provided by Actelion:

Primary Outcome Measures:

Liver Volume [ Time Frame: baseline to end of treatment (month 24 or imputed value) ]
Liver volume was assessed at baseline and end of treatment by magnetic resonance imaging
Percent Change in Liver Volume [ Time Frame: baseline to end of treatment (month 24 or imputed value) ]
Liver volume was assessed at baseline and end of treatment by magnetic resonance imaging

Secondary Outcome Measures:

Spleen Volume [ Time Frame: baseline to end of treatment (month 24 or imputed value) ]
Spleen volume was assessed at baseline and end of treatment by magnetic resonance imaging
Percent Change in Spleen Volume [ Time Frame: baseline to end of treatment (month 24 or imputed value) ]
Spleen volume was assessed at baseline and end of treatment by magnetic resonance imaging


Enrollment:	42
Study Start Date:	February 2006
Study Completion Date:	July 2010
Primary Completion Date:	June 2010 (Final data collection date for primary outcome measure)

Arms	Assigned Interventions
Experimental: 1	Drug: miglustat miglustat oral capsules 100mg three times daily (TID) Other Name: Zavesca

Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:	18 Years and older (Adult, Senior)
Sexes Eligible for Study:	All
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Males or females aged 18 years or older
Type 1 Gaucher disease, diagnosed by glucocerebrosidase assay or molecular analysis of the glucocerebrosidase gene.
Treatment with ERT for at least 3 years, with a stable dose regimen for at least the last 6 months.
Clinically and biologically stable disease for the previous 2 years, with at least 2 time points assessments (including Baseline as one potential time point), defined as:
- Stable organomegaly (assessed by magnetic resonance imaging (MRI) or computed tomography (CT)):
  - Liver volume within 10% of the mean.
  - Spleen volume within 10% of the mean.
- Free of progressive symptomatic documented bone disease.
- Hemoglobin levels > 11g/dl
- Mean platelet count > 100x109 /l.
- Chitotriosidase activity within 20% of the mean. - If chitotriosidase is not available (in the case of chitotriosidase deficiency, or if it was not determined), other relevant biomarkers (e.g., angiotensin converting enzyme (ACE), tartrate resistant acid phosphatase (TRAP) and ferritin) could be considered.
Written informed consent.

Exclusion Criteria:

History or evidence of oculomotor gaze palsy, ataxia or other clinical manifestations typically associated with neuronopathic type 3 Gaucher disease.
Not ambulant patients, or with progressive symptomatic documented bone disease.
Splenectomy before 18 years of age for splenomegaly and/or thrombocytopenia.
Peripheral polyneuropathy (not mononeuropathy) documented with both clinical signs and symptoms, and electrodiagnostic (EDX).
Patients (males and females) who do not agree to use reliable contraception throughout the study and for 3 months after cessation of miglustat treatment.
Female patients who are pregnant or breast feeding, or without pregnancy test prior to Day 1.
History of significant lactose intolerance.
Clinically significant diarrhea (>3 liquid stools per day for >7 days) without definable cause within 6 months prior to Day 1, or a history of clinically relevant gastrointestinal disorders.
History of cataracts or known increased risk of cataract formation.
Severe renal impairment i.e., with a creatinine clearance <30 ml/min/1.73m^2
Concomitant active medical condition such as human immunodeficiency virus (HIV) or hepatitis B/C that would render patients unsuitable for study.
Previous treatment with miglustat.

Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00319046

Show 20 Study Locations

Sponsors and Collaborators

Actelion

Investigators


Principal Investigator:	Timothy Cox, Prof	University of Cambridge

More Information

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Cox TM, Amato D, Hollak CE, Luzy C, Silkey M, Giorgino R, Steiner RD; Miglustat Maintenance Study Group. Evaluation of miglustat as maintenance therapy after enzyme therapy in adults with stable type 1 Gaucher disease: a prospective, open-label non-inferiority study. Orphanet J Rare Dis. 2012 Dec 27;7:102. doi: 10.1186/1750-1172-7-102.


Responsible Party:	Actelion
ClinicalTrials.gov Identifier:	NCT00319046 History of Changes
Other Study ID Numbers:	OGT 918-011
First Submitted:	April 26, 2006
First Posted:	April 27, 2006
Results First Submitted:	April 24, 2012
Results First Posted:	May 23, 2012
Last Update Posted:	June 1, 2012
Last Verified:	May 2012

Keywords provided by Actelion:


Type 1 Gaucher Disease miglustat enzyme replacement therapy

Additional relevant MeSH terms:


Gaucher Disease Sphingolipidoses Lysosomal Storage Diseases, Nervous System Brain Diseases, Metabolic, Inborn Brain Diseases, Metabolic Brain Diseases Central Nervous System Diseases Nervous System Diseases Metabolism, Inborn Errors Genetic Diseases, Inborn Lipidoses Lipid Metabolism, Inborn Errors Lysosomal Storage Diseases	Metabolic Diseases Lipid Metabolism Disorders Miglustat 1-Deoxynojirimycin Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action Anti-HIV Agents Anti-Retroviral Agents Antiviral Agents Anti-Infective Agents Glycoside Hydrolase Inhibitors Hypoglycemic Agents Physiological Effects of Drugs

To Top